AMITRIPTYLINE MARKET ANALYSIS

Global amitriptyline market is estimated to be valued at US$ 607.0 Million in 2023 and is expected to exhibit a CAGR of 5.6% during the forecast period (2023-2030). An increase in product launches by the key market players is expected to drive the market growth over the forecast period. Moreover, an increase in the prevalence of anxiety and migraine is expected to drive the market growth.

Analysts’ Views on Global Amitriptyline Market:

The global amitriptyline market growth can be restricted by various side effects associated with the use of amitriptyline. The side effects of amitriptyline include nausea, vomiting, drowsiness, weakness or tiredness, nightmares, headaches, dry mouth, constipation, changes in sex drive, and others. Thus, side effects associated with the drug can shift the patient’s preference to alternative treatments. Such factors are expected to hamper the growth of the market.

Figure 1. Global Amitriptyline Market Share (%), By Strength, 2023

To learn more about this report, request sample copy

Global Amitriptyline Market- Driver

Increase in the product approval by regulatory authorities: An increase in the number of product approval by regulatory authorities such as the U.S. FDA is expected to drive the market growth over the forecast period. For instance, in May 2021, Unichem Laboratories Ltd., an India-based pharmaceutical company, announced that it had received Abbreviated New Drug Application (ANDA) approval for its Amitriptyline HCl Tablets USP, 10 mg, 25 mg, 50 mg, 75 mg, 100 mg and 150 mg from the U.S. Food and Drug Administration (USFDA), to market a generic version of ELAVIL (Amitriptyline Hydrochloride) in U.S.

Rising prevalence of mental disorders such as depression: The demand for amitriptyline is expected to increase, owing to the rise in the prevalence of mental disorders such as depression, anxiety, and others. Amitriptyline is a tricyclic antidepressant primarily used to treat major depressive disorder, a variety of pain syndromes such as neuropathic pain, fibromyalgia, migraine and tension headaches. For instance, according to the fact sheet published by WHO (World Health Organization), on March 31, 2023, depression is a common mental disorder and an estimated 5% of adults suffer from depression, globally.

Figure 2. Global Amitriptyline Market Share (%), By Region, 2023

To learn more about this report, request sample copy

Global Amitriptyline Market- Regional Analysis

Among all regions, North America is expected to dominate the market over the forecast period. This is attributed to North America holding a 34.8% market share and the presence of major players such as Accord Healthcare Inc., Viatris Inc., Sun Pharmaceutical Industries Inc., and others, contributing to the development of the amitriptyline market in North America.

The Europe region is expected to be the second dominating region over the forecast period, due to an increase in the cases of mental disorders. For instance, according to the fact sheet published by WHO (World Health Organization), on March 31, 2023, there were more than 150 million people living with mental disorder in Europe in 2021.

Global Amitriptyline Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak, in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 has affected the economy in three main ways: by directly affecting the production and demand for drugs and vaccines, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others faced problems with regard to the transportation of drugs and vaccines from one place to another.

Quarantine, traveling constraints, and social distancing measures are likely to lead to a steep decline in business and consumer spending. Furthermore, healthcare providers were facing challenges in terms of additional manpower, equipment, consumables, and other resources which were required to ensure safety in hospitals and provide treatment to patients with other diseases. This has impacted the overall healthcare market negatively.

However, the COVID-19 pandemic had a positive impact on the global amitriptyline market due to increasing use of amitriptyline to treat post COVID-19 symptoms. For instance, according to an article published in National Library of Medicine, in July 2021, titled “Amitriptyline for post-COVID headache: effectiveness, tolerability, and response predictors,” headache is one of the most frequent symptoms of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and amitriptyline was found effective to treat patient with post-COVID-19 symptoms such as headache, migraine, and others.

Moreover, COVID-19 pandemic has increased the prevalence of mental disorder, thus, it is also expected to have had positive impact on the market. For instance, according to WHO, in March 2022, the COVID-19 pandemic has had a severe impact on the mental health and wellbeing of people around the world, and also raising concerns of increased suicidal behavior and increased mental disorders.

Global Amitriptyline Market Segmentation:

Global amitriptyline market report is segmented into strength, indication, distribution channel and region

• Based on strength, the market is segmented into 10 mg tablets, 25 mg tablets, 50 mg tablets, 75 mg tablets, 100 mg tablets, and 150 mg tablets. Out of which, the 10 mg tablets segment is expected to dominate the global amitriptyline market during the forecast period, and this is attributed to an increase in the product launched by key market players.
• Based on indication, the market is segmented into depression, nocturnal enuresis, migraine, chronic neuropathic pain, and others. Out of which, the depression segment is expected to dominate the global amitriptyline market during the forecast period, and this is attributed to an increase in the prevalence of depression globally.
• Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Out of which, the hospital pharmacies segment is expected to dominate the market over the forecast period and this is attributed to an increase in the number of hospitals and number of patient visits in hospital globally.

Among all segmentation, the distribution channel segment has the highest potential due to an increase in the number of pharmacies in the U.S. For instance, according to an article published by The Commonwealth Fund, a private U.S.-based foundation involved in providing standard health care services, in August 2021, there are roughly 60,000 retail pharmacies in the U.S., and one-third are independent pharmacies and two-thirds are retail chains, supermarkets, and mass retailers.

Global Amitriptyline Market Cross-Sectional Analysis: In the distribution channel segment, the hospitals pharmacies segment held a dominant position in the Asia Pacific region, due to an increase in the number of hospitals and hospital pharmacies in this region. For instance, according to an article published by Asian Hospital & Healthcare Management, in December 2022, there were more than 36,570 hospitals in China, in the year 2021. Thus, the rising number of hospitals will eventually increase the number of hospital pharmacies and drive the market growth.

Global Amitriptyline Market: Key Developments

• On March 30, 2023, AlgoTx, a France-based clinical stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had cleared the Investigational New Drug Application (IND) for its Phase 2 first-in-class candidate ATX01 (amitriptyline) in the treatment of erythromelalgia.
• On March 30, 2023, AlgoTx, a France-based clinical stage biotechnology company, announced that the first patients have been randomized into the “ATX01 for the pain of ChemoTherapy” (ACT) study in Chemotherapy-Induced Peripheral Neuropathy (CIPN)

Global Amitriptyline Market: Restraint

Increase in the product recall: The major factors that can hamper the growth of the global amitriptyline market over the forecast period include the rise in the number of product recall. For instance, in February 2023, Apotex Inc., a Canada based pharmaceutical company, announced that they have recalled one lot of APO-Amitriptyline 10 mg tablets due to the presence of N-nitrosodimethylamine (NDMA), a nitrosamine impurity, above the acceptable limit. Key market players should focus on more stringent quality control and Good Manufacturing Practices (GMP) to obtain superior product quality.

Key market players should focus on adoption of good manufacturing practices (GMP) to reduce the contamination of their products

Global Amitriptyline Market: Key Players

Major players operating in the global amitriptyline market include Accord Healthcare Inc., Viatris Inc., Sandoz Inc., Sun Pharmaceutical Industries Inc., Vintage Pharmaceuticals Inc., Zydus Pharmaceuticals USA Inc., Watson laboratories Inc., Torrent Pharmaceuticals Ltd., Dr Reddy's Laboratories Ltd., Unichem Laboratories Ltd., Apotex Inc., and Intas Pharmaceuticals Ltd.

Definition: Amitriptyline belongs to the class of drugs known as tricyclic antidepressants. Amitriptyline functions by boosting serotonin levels in the brain. Serotonin is a neurotransmitter, a chemical that the brain releases to nerves throughout the body.